<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="proliferate">
            <roleset id="proliferate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="thing becoming abundant&#x09;&#x09;&#x09;&#x09;// gene products //&#x0A;" />
                    <role n="1" descr="situation of becoming abundant&#x0A;" />
                    <role n="2" descr="location referring to organ, vitro&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>Cancer cells may be proliferate by increased proliferation or scheduled cell death.</text>
                </example>
                <example src="EGRAM" no="1">
                    <text>These results show that intraspontically transplanted fetal cells are able to proliferate and differentiate into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>Adult T cells at rest, under normal conditions, may proliferate strongly after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Adult T cells, at rest under normal conditions, have the ability to proliferate strongly after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>After androgen withdrawal and angiogen treatment, Stat5ab-/-peripheral T cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>After androgen withdrawal and angiogen treatment, androgenic responsive prostate cancer cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen prostate cancer cells will proliferate tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>After the androgen has been withdrawn and angiogen treatment, prostate cancer cells respond to androgen will proliferate tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>HSC continued to proliferate in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>HSC is able to continue to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>HSC may continue to proliferate in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>HSC may have continued to proliferate in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>HSC will continue to proliferate in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>It is observed that adult T cells regains the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Our observations illustrate that adult T cells can be endowed with biochemical machinery to proliferate when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Our observations illustrate that endothelial cells is endowed with biochemical machinery to proliferate indefinitely when exposed to FGF2, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Our observations illustrate that stat5ab/peripheral T cells could have been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Stat5ab-/-peripheral T cells can regain the ability to proliferate indefinitely after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, will proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that was observed to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that can proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Treatment of allergen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>androgen tumour cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>stat5ab-/-peripheral T cells, which are at rest in normal conditions, will proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>stat5ab-/-peripheral T cells, which are at rest in normal conditions, will proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>After androgen withdrawal and angiogen treatment, adult T cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splintly transplanted fetal shapes will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplintly transplanted fetal cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplintly transplanted fetal cells will proliferate tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>The treatment of intrasponntically transplanted fetal cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>Treatment of CD4+ HIV T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>Treatment of EBD cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>Treatment of TBI cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>adult T cells, which are at rest in normal conditions, have the ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>androgen cancer cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>intra-splenic transplant fetal cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>intraspontically transplanted fetal cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>the human placenta, which are at rest under normal conditions, are able to proliferate strongly through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>the human placenta, which are at rest under normal conditions, are able to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>the human placenta, which are at rest under normal conditions, will proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
